Trial Profile

Extension study of SEISMiC Phase 2 Study of Istaroxime in Early Cardiogenic Shock cardiogenic shock due to heart failure(SEISMiC B)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 23 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

16 Jun 2025 According to a Windtree Therapeutics media release, company announced that the data from this SEISMiC B study has been published in the Journal of Heart and Lung Transplantation.
19 May 2025 According to a Windtree Therapeutics media release, company will present data from this SEISMiC Extension Phase 2b study at the European Society of Cardiology Heart Failure 2025 Conference in Belgrade, Serbia.
16 Dec 2024 Status changed from active, no longer recruiting to completed According to a Windtree Therapeutics media release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com